Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal

Fineline Cube Feb 10, 2026
Company Deals

Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million

Fineline Cube Feb 10, 2026
Company Deals

Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal

Fineline Cube Feb 10, 2026
Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Fineline Cube Feb 10, 2026
Company Deals

Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Deals

Dartsbio Licenses Potential First-in-Class BsAb DS005 to Duality Biologics

Fineline Cube Nov 3, 2022

China-based Dartsbio Pharmaceuticals, Ltd has announced a licensing deal with Duality Biologics, a novel modality...

Company Deals

Fosun Pharma Terminates Equity Transfer Deal with OncoCare Medical

Fineline Cube Nov 3, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the termination of...

Company Drug

Antengene’s CD73 Inhibitor ATG-037 Greenlit for Phase I Study by NMPA

Fineline Cube Nov 3, 2022

China-based Antengene Corporation Limited (HKG: 6996) has announced receiving approval from the National Medical Products...

Company Medical Device

Sino Medical Sciences’ Non-Compliant Balloon Catheter Approved by NMPA

Fineline Cube Nov 3, 2022

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving market approval from the...

Company Drug

Hengrui’s Pyrotinib Granted Breakthrough Therapy Designation by CDE

Fineline Cube Nov 3, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Hengrui Medicine Co., Ltd’s (SHA:...

Company Drug

NMPA Approves Humanwell’s Generic Clobazam for Lennox-Gastaut Syndrome

Fineline Cube Nov 3, 2022

China-based Yichang Humanwell Pharmaceutical Co., Ltd’s generic version (oral suspension) of Sanofi’s clobazam (trade name:...

Company Drug

NMPA Approves Luye Pharma’s LY03005 for Depression Treatment

Fineline Cube Nov 3, 2022

China-based Luye Pharma Group (HKG: 2186) has announced that its Category 1 chemical drug LY03005...

Company Drug Policy / Regulatory

Shanghai SMPA Suspends HEC’s Linagliptin Procurement Over Patent Infringement

Fineline Cube Nov 3, 2022

The Shanghai Sunshine Medical Procurement All-in-One (SMPA) platform has revealed that it has suspended the...

Company Drug

Shanghai Pharmaceuticals Gets NMPA Clearance for Sublingual Rasagiline

Fineline Cube Nov 3, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has announced receiving clinical clearance from the National Medical...

Company Deals

Baidu Health Partners with Shanghai Epiprobe for Cancer Early Screening

Fineline Cube Nov 3, 2022

China Internet giant Baidu’s Health Internet Hospital unit has announced a partnership with Shanghai Epiprobe...

Company Deals

Pharmaniaga Partners with JD.com to Enter China Market

Fineline Cube Nov 3, 2022

Malaysia-based pharma company Pharmaniaga Berhad (Pharmaniaga) is planning to bring its products into mainland China...

Company Drug

Eli Lilly’s Peresolimab and LOXO-783 Gain Tacit Clinical Trial Approvals in China

Fineline Cube Nov 2, 2022

The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approvals to...

Company Drug

Hua Medicine Launches Dorzagliatin, a First-in-Class Diabetes Drug, in China

Fineline Cube Nov 2, 2022

China-based Hua Medicine has announced the commercial launch of its Category 1 drug, dorzagliatin, with...

Company Medical Device

Yiming and Hexaell’s HepaCure Biocolumn Receives IND Approval for HBV-Induced Liver Failure

Fineline Cube Nov 2, 2022

China-based Yiming (Beijing) Cell Biotechnology Co., Ltd (also known as Ubrigene) and its partner Shanghai...

Company Drug

Yiming and Vitalgen’s Gene Therapy VGR-R01 Receives CDE Approval for Bietti Crystalline Dystrophy

Fineline Cube Nov 2, 2022

China-based Yiming (Beijing) Cell Biotechnology Co., Ltd (also known as Ubrigene) and its partner Shanghai...

Company Drug

LianBio’s TP-03 Begins Phase III Trial for Demodectic Blepharitis in China

Fineline Cube Nov 2, 2022

Shanghai-based biopharmaceutical company LianBio (OTCMKTS: LIANY) has announced the first patient dosing in a Phase...

Company Drug

Ascletis Files IND Application for COVID-19 Oral Inhibitor ASC11 with FDA

Fineline Cube Nov 2, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has announced that the Investigational New Drug (IND) application...

Company Drug

RemeGen’s Telitacicept Shows Positive Results in Phase II Myasthenia Gravis Study

Fineline Cube Nov 2, 2022

China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has released data from a Phase II...

Company Deals

Immunochina Pharmaceuticals Raises Funds for Gene Therapy Development

Fineline Cube Nov 2, 2022

Beijing-based gene therapy specialist Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in...

Company Medical Device

BGI Genomics Receives NMPA Approval for Chromosome Aneuploidy Detection Kit

Fineline Cube Nov 2, 2022

China-based genomics firm BGI Genomics Co., Ltd (SHE: 300676), the Shenzhen-listed subsidiary of BGI Group,...

Posts pagination

1 … 563 564 565 … 622

Recent updates

  • Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal
  • Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million
  • Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal
  • Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million
  • Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal

Company Deals

Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million

Company Deals

Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal

Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.